Literature DB >> 32503915

Checking autoimmune genetic risk to stratify immune checkpoint inhibitor responders.

Animesh A Sinha1.   

Abstract

Year:  2020        PMID： 32503915      PMCID： PMC7321960          DOI： 10.1073/pnas.2007744117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  12 in total

1.  Predictors of response and resistance to checkpoint inhibitors in solid tumors.

Authors:  Sanjana V Rao; Amy E Moran; Julie N Graff
Journal:  Ann Transl Med       Date:  2017-12

2.  Trends in clinical development for PD-1/PD-L1 inhibitors.

Authors:  Jia Xin Yu; Jeffrey P Hodge; Cristina Oliva; Svetoslav T Neftelinov; Vanessa M Hubbard-Lucey; Jun Tang
Journal:  Nat Rev Drug Discov       Date:  2020-03       Impact factor: 84.694

3.  Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.

Authors:  Megan Greally; Joanne F Chou; Walid K Chatila; Matthew Margolis; Marinela Capanu; Jaclyn F Hechtman; Yaelle Tuvy; Ritika Kundra; Foysal Daian; Marc Ladanyi; David P Kelsen; David H Ilson; Michael F Berger; Laura H Tang; David B Solit; Luis A Diaz; Nikolaus Schultz; Yelena Y Janjigian; Geoffrey Y Ku
Journal:  Clin Cancer Res       Date:  2019-07-23       Impact factor: 12.531

4.  Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study.

Authors:  Yasuhiro Nakamura; Ryota Tanaka; Yuri Asami; Yukiko Teramoto; Taichi Imamura; Sayuri Sato; Hiroshi Maruyama; Yasuhiro Fujisawa; Taisuke Matsuya; Manabu Fujimoto; Akifumi Yamamoto
Journal:  J Dermatol       Date:  2016-08-11       Impact factor: 4.005

Review 5.  Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.

Authors:  Jun Gong; Alexander Chehrazi-Raffle; Srikanth Reddi; Ravi Salgia
Journal:  J Immunother Cancer       Date:  2018-01-23       Impact factor: 13.751

Review 6.  Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer.

Authors:  Ewelina Grywalska; Marcin Pasiarski; Stanisław Góźdź; Jacek Roliński
Journal:  Onco Targets Ther       Date:  2018-10-04       Impact factor: 4.147

Review 7.  Application of PD-1 Blockade in Cancer Immunotherapy.

Authors:  Xiaomo Wu; Zhongkai Gu; Yang Chen; Borui Chen; Wei Chen; Liqiang Weng; Xiaolong Liu
Journal:  Comput Struct Biotechnol J       Date:  2019-05-23       Impact factor: 7.271

Review 8.  Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review.

Authors:  Vito Longo; Oronzo Brunetti; Amalia Azzariti; Domenico Galetta; Patrizia Nardulli; Francesco Leonetti; Nicola Silvestris
Journal:  Cancers (Basel)       Date:  2019-04-15       Impact factor: 6.639

9.  Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer.

Authors:  Zia Khan; Flavia Di Nucci; Antonia Kwan; Christian Hammer; Sanjeev Mariathasan; Vincent Rouilly; Jonathan Carroll; Magnus Fontes; Sergio Ley Acosta; Ellie Guardino; Haiyin Chen-Harris; Tushar Bhangale; Ira Mellman; Jonathan Rosenberg; Thomas Powles; Julie Hunkapiller; G Scott Chandler; Matthew L Albert
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-19       Impact factor: 11.205

10.  Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis.

Authors:  Leitao Sun; Leyin Zhang; Jieru Yu; Yinan Zhang; Xi Pang; Chenghao Ma; Minhe Shen; Shanming Ruan; Harpreet S Wasan; Shengliang Qiu
Journal:  Sci Rep       Date:  2020-02-07       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.